The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes.
 
Guillermo Montalban-Bravo
Research Funding - Solu Therapeutics; Takeda
 
Nicholas Short
Honoraria - Amgen
Consulting or Advisory Role - Amgen; AstraZeneca; NGM Biopharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Astellas Pharma; Stemline Therapeutics; Takeda
 
Naval Daver
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)
 
Yesid Alvarado
No Relationships to Disclose
 
Kelly Chien
Honoraria - Abbvie
Consulting or Advisory Role - Rigel
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma; Autolus; Bristol-Myers Squibb; Genentech; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; TargetRX; Terns Pharmaceuticals
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Terns Pharmaceuticals; TGRX
Travel, Accommodations, Expenses - Aptitude Health; Autolus; Daiichi Sankyo Nordics; HMP Education; MD Education; Nucleus Global; ONVIV; Pfizer
 
Gautam Borthakur
Consulting or Advisory Role - Abbvie; Argenx; BiolineRx; BioTheryX; Catamaran Bio; Nkarta; Novartis; PTC Therapeutics; Takeda; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Arvinas (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BiolineRx (Inst); BioTheryX (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Cyclacel (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); MedImmune (Inst); Mundipharma Research (Inst); Nkarta (Inst); Nkarta (Inst); Novartis (Inst); Oncoceutics (Inst); PTC Therapeutics (Inst); Ryvu Therapeutics (Inst); TCR2 Therapeutics (Inst); Treadwell Therapeutics (Inst); XBiotech (Inst)
 
Mahesh Swaminathan
No Relationships to Disclose
 
Abhishek Maiti
Research Funding - Celgene (Inst); Chimeric Therapeutics (Inst); CytoMed Therapeutics (Inst); Indapta Therapeutics (Inst); Lin BioScience (Inst)
 
Danielle Hammond
No Relationships to Disclose
 
Ghayas Issa
Consulting or Advisory Role - Abbvie; Kura Oncology; Novartis; NuProbe; Sanofi; Syndax
Research Funding - Astex Pharmaceuticals (Inst); Cullinan Oncology; Kura Oncology (Inst); Merck; Novartis (Inst); NuProbe (Inst); Syndax (Inst)
 
Lucia Masarova
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Cogent Biosciences; Pharmaessentia
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - MorphoSys
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; Cogent Biosciences; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Ionis Pharmaceuticals; Jubilant Therapeutics; Karyopharm Therapeutics; Morphic Therapeutic; MorphoSys; Novartis; Pharmaessentia
Consulting or Advisory Role - Ono Pharmaceutical; Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst); Telios (Inst)
 
Xuelin Huang
No Relationships to Disclose
 
Heather Schneider
No Relationships to Disclose
 
Kristy Bodden
No Relationships to Disclose
 
Lizabeth Romero
No Relationships to Disclose
 
Tapan Kadia
Honoraria - CURE
Consulting or Advisory Role - Abbvie/Genentech; Agios; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/UCB Japan; Jazz Pharmaceuticals; Liberum; Novartis; Pfizer; Pinot Bio; Sanofi; Sellas Life Sciences; SERVIER
Research Funding - Abcuro; Amgen; Ascentage Pharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Celgene; cellenkos; Cyclacel; DAAN Biotherapeutics; Delta-Fly Pharma; Genentech/Abbvie; Genfleet Therapeutics; Glycomimetics; Incyte; Iterion Therapeutics; Jazz Pharmaceuticals; Pfizer; Pulmotech; Regeneron (Inst); Sellas Life Sciences
 
Hagop Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; KAHR Medical; Novartis; Pfizer; Shenzhen Target Rx
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Guillermo Garcia-Manero
Honoraria - Ascentage Pharma; Bristol-Myers Squibb/Celgene; Curis; Keros Therapeutics; SERVIER; Taiho Oncology
Consulting or Advisory Role - Ascentage Pharma; Bristol-Myers Squibb; Curis; Keros Therapeutics; SERVIER; Taiho Oncology
Research Funding - Abbvie; Bristol-Myers Squibb; Chordia Therapeutics; Curis; Genentech; Jazz Pharmaceuticals; Novartis; Rigel; Stemline Therapeutics; Taiho Oncology; Zentalis